PMID- 28566170
OWN - NLM
STAT- MEDLINE
DCOM- 20180314
LR  - 20180314
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 378
DP  - 2017 Jul 15
TI  - Is maraviroc useful in multiple sclerosis patients with natalizumab-related
      progressive multifocal leukoencephalopathy?
PG  - 233-237
LID - S0022-510X(17)30314-3 [pii]
LID - 10.1016/j.jns.2017.05.018 [doi]
AB  - BACKGROUND: Despite the recent advances in the understanding of natalizumab (NTZ)
      related progressive multifocal leukoencephalopathy (PML) and its associated
      immune reconstitution inflammatory syndrome (PML-IRIS), the therapeutic options
      are still under investigated. In this context, the beneficial use of maraviroc is
      still an anecdotal observation. OBJECTIVE: To evaluate the impact of maraviroc in
      modifying the course of PML preventing IRIS or blunting IRIS manifestations.
      METHODS: Three patients with NTZ PML included in the Italian dataset of PML were 
      treated with maraviroc. Their longitudinal clinical and radiological course was
      described in detail. RESULTS: The three patients were characterized by a steady
      clinical worsening not controlled by maraviroc. All the three patients manifested
      PML-IRIS, which emerged, respectively, at 62, 64 and 90days post NTZ withdrawal. 
      This is in accordance with the data of the Italian dataset. Clinical and
      radiological stabilization of PML-IRIS occurred only after corticosteroids
      administration. CONCLUSION: In these three cases, maraviroc did not show any
      clear effect in modulating the clinical course of PML preventing IRIS. Moreover, 
      once PML-IRIS emerged, the clinical stabilization was achieved only with the use 
      of corticosteroids. Thus, the use of maraviroc should be regarded with extreme
      caution due the potential adverse events associated with its use.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Scarpazza, Cristina
AU  - Scarpazza C
AD  - Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018
      Montichiari, Brescia, Italy.
FAU - Prosperini, Luca
AU  - Prosperini L
AD  - Department of Neurology and Psychiatry, Sapienza University, Viale
      Dell'Universita, 30, 00185 Rome, Italy.
FAU - Mancinelli, Chiara R
AU  - Mancinelli CR
AD  - Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018
      Montichiari, Brescia, Italy.
FAU - De Rossi, Nicola
AU  - De Rossi N
AD  - Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018
      Montichiari, Brescia, Italy.
FAU - Lugaresi, Alessandra
AU  - Lugaresi A
AD  - Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum,
      Universita di Bologna, Italy; IRCCS Istituto delle Scienze, "UOSI Riabilitazione 
      Sclerosi Multipla", Via Altura 3, 40138 Bologna, Italy.
FAU - Capobianco, Marco
AU  - Capobianco M
AD  - SCDO Neurologia 2, Centro di Riferimento Regionale Sclerosi Multipla, AOU San
      Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Torino, Italy.
FAU - Moiola, Lucia
AU  - Moiola L
AD  - Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San
      Raffaele University, Via Olgettina 48, 20132 Milan, Italy.
FAU - Naldi, Paola
AU  - Naldi P
AD  - Multiple Sclerosis Centre, Clinica Neurologica, AOU "Maggiore della Carita"
      Novara, Corso Mazzini 18, 28100 Novara, Italy.
FAU - Imberti, Luisa
AU  - Imberti L
AD  - Centro Ricerca Emato-oncologia AIL (CREA), Diagnostics Department, Spedali Civili
      of Brescia, Piazzale Spedali Civili, 1, 25123 Brescia, Italy.
FAU - Gerevini, Simonetta
AU  - Gerevini S
AD  - Department of Neuroradiology, San Raffaele Scientific Institute, Vita-Salute San 
      Raffaele University, Via Olgettina 60, 20132 Milan, Italy.
FAU - Capra, Ruggero
AU  - Capra R
AD  - Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018
      Montichiari, Brescia, Italy. Electronic address: ruggero.capra@gmail.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170512
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Cyclohexanes)
RN  - 0 (Immunologic Factors)
RN  - 0 (Natalizumab)
RN  - 0 (Triazoles)
RN  - 0 (Viral Fusion Protein Inhibitors)
RN  - MD6P741W8A (maraviroc)
SB  - IM
MH  - Adult
MH  - Brain/diagnostic imaging/drug effects
MH  - Cyclohexanes/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/diagnostic imaging/drug
      therapy/etiology
MH  - Immunologic Factors/*adverse effects/therapeutic use
MH  - Leukoencephalopathy, Progressive Multifocal/diagnostic imaging/*drug
      therapy/etiology/immunology
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/complications/diagnostic imaging/*drug therapy/immunology
MH  - Natalizumab/*adverse effects/therapeutic use
MH  - Treatment Failure
MH  - Triazoles/*therapeutic use
MH  - Viral Fusion Protein Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Immune reconstitution inflammatory syndrome
OT  - Maraviroc
OT  - Natalizumab
OT  - Progressive multifocal leukoencephalopathy
EDAT- 2017/06/02 06:00
MHDA- 2018/03/15 06:00
CRDT- 2017/06/02 06:00
PHST- 2017/03/14 00:00 [received]
PHST- 2017/04/21 00:00 [revised]
PHST- 2017/05/10 00:00 [accepted]
PHST- 2017/06/02 06:00 [entrez]
PHST- 2017/06/02 06:00 [pubmed]
PHST- 2018/03/15 06:00 [medline]
AID - S0022-510X(17)30314-3 [pii]
AID - 10.1016/j.jns.2017.05.018 [doi]
PST - ppublish
SO  - J Neurol Sci. 2017 Jul 15;378:233-237. doi: 10.1016/j.jns.2017.05.018. Epub 2017 
      May 12.